- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01517984
Immunmonitoring és CNI-megvonás alacsony kockázatú veseátültetésben részesülőknél
Immunmonitoring és kalcineurin-inhibitor (CNI) megvonása alacsony kockázatú vesetranszplantáción átesett betegeknél
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
California
-
Los Angeles, California, Egyesült Államok, 90055
- University of California Los Angeles
-
-
Connecticut
-
New Haven, Connecticut, Egyesült Államok, 06520-8029
- Yale University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Egyesült Államok, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Egyesült Államok, 48109
- University of Michigan Hospital
-
-
Missouri
-
St Louis, Missouri, Egyesült Államok, 63110
- Washington University
-
-
New York
-
New York, New York, Egyesült Államok, 10029
- Mount Sinai School of Medicine
-
-
Ohio
-
Cleveland, Ohio, Egyesült Államok, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Egyesült Államok, 44106-5048
- University Hospitals of Cleveland
-
-
Texas
-
Houston, Texas, Egyesült Államok, 77030
- The Methodist Hospital
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3A IR9
- Health Sciences Centre
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M1
- Toronto General Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
INCLUSION CRITERIA -
Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:
- Subject must be able to understand and provide written informed consent;
- Primary living-donor (related or unrelated) kidney transplant recipients;
- Peak flow-based PRAs for class I and class II <30%(performed by local center);
- Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
- No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
- Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
- Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
- Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.
Inclusion Criteria for Randomization:
Participants who meet all of the following criteria are eligible for randomization:
- No history of acute rejection episodes;
- The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
- No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).
EXCLUSION CRITERIA -
Initial Enrollment/Screening:
Participants who meet any of these criteria are not eligible for enrollment as study subjects:
- Recipient of multiple organ transplants;
- Prior history of organ transplantation;
- Deceased-donor source;
- Any condition that would preclude protocol biopsies;
- HLA identical recipients;
- Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
- Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
- Inability or unwillingness to comply with study protocol;
- Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.
Exclusion Criteria for Randomization:
Participants who meet any of these criteria are not eligible for randomization:
- Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
- Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
- Any condition that would preclude protocol biopsies;
- Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
- Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
- Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
- Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
- Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Tacrolimus (CNI) Withdrawal
Subjects randomized (2:1) to tacrolimus (CNI) withdrawal. Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal. |
Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.
Más nevek:
Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Más nevek:
|
|
Aktív összehasonlító: Standard Immunosuppressive Therapy
Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal. Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur. |
Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization
Időkeret: IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.
|
The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules. |
IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation
Időkeret: 6 months post-transplantation, 24 months post-transplantation
|
Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function |
6 months post-transplantation, 24 months post-transplantation
|
|
Incidence of Acute Rejection
Időkeret: 6 to 18 months post-randomization
|
Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events. |
6 to 18 months post-randomization
|
|
Allograft Survival Rate
Időkeret: 6 to 18 months post-randomization
|
Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study. |
6 to 18 months post-randomization
|
|
Participant Survival Rate
Időkeret: 6 to 18 months post-transplantation
|
Number of participants who did not die within the course of this study. |
6 to 18 months post-transplantation
|
|
Percentage of Participants With New Donor Specific Antibodies (DSAs)
Időkeret: 6 to 18 months post-randomization
|
Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection. |
6 to 18 months post-randomization
|
|
Percentage of Participants With Donor-Specific Memory Using Elispot
Időkeret: 6 to 18 months post-randomization
|
This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met. |
6 to 18 months post-randomization
|
|
Percentage of Participants in the Experimental Arm Off Tacrolimus
Időkeret: 18 months post-randomization
|
Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies. |
18 months post-randomization
|
|
Incremental Change in IF/TA Scores
Időkeret: 6 to 18 months post-transplant
|
This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met. |
6 to 18 months post-transplant
|
|
Measurement of Urinary Parameters Before and After Randomization
Időkeret: 6 months post-transplantation to 18 months post-randomization
|
This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met. |
6 months post-transplantation to 18 months post-randomization
|
Együttműködők és nyomozók
Együttműködők
Nyomozók
- Tanulmányi szék: Donald Hricik, MD, University Hospitals Cleveland Medical Center
- Kutatásvezető: Peter S. Heeger, MD, Icahn School of Medicine at Mount Sinai
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becsült)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- A farmakológiai hatás molekuláris mechanizmusai
- Enzim gátlók
- Szerves vegyi anyagok
- Zsírsavak
- Lipidek
- Farmakológiai intézkedések
- Kémiai tevékenységek és felhasználások
- Savak, aciklusos
- Karbonsavak
- Policiklusos vegyületek
- Terhesség
- Terhesség
- Szteroidok
- Olvasztott gyűrűs vegyületek
- Makrolidok
- Laktonok
- Szurkolók
- Kaprosák
- Prednizon
- Mikofenolsav
- Takrolimusz
- Kalcineurin inhibitorok
- timoglobulin
- cni fehérje, Drosphila
Egyéb vizsgálati azonosító számok
- DAIT CTOT-09
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .